

ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)

Adelaide, Australia

Date: 22 December, 2017

Release: Immediate

Topic: Share Purchase Plan and Tranche 2 Placement



Adelaide, Australia, 22 December, 2017 – Ellex Medical Lasers Limited (ASX:ELX) (“Ellex”), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that applications under the Share Plan (“SPP”) announced on 3 November 2017 and dispatched to shareholders on 14 November 2017, closed on 13 December 2017 with applications received for approximately 555,000 shares.

Ellex has issued approximately 555,000 fully paid ordinary shares under the SPP, which were allotted at \$1.05 per share, the same price that applied to the private placement announced by Ellex on 3 November 2017 (“Placement”). The shares issued under the SPP rank equally with the shares currently on issue in Ellex.

SPP shares were issued on 20 December 2017 and an Appendix 3B is lodged with ASX on 22 December 2017 for the commencement of trading. Holding statements were despatched to participating shareholders on 21 December 2017.

Under Tranche 2 of the Placement, Ellex allotted 11,777,522 shares after receiving shareholder approval at a General Meeting held on 8 December 2017.

This completes both the Share Purchase Plan and Placement to institutional and sophisticated investors announced on 3 November 2017.

The combination of both the SPP and the Placement has resulted in an allotment of approximately 22.5 million fully paid ordinary shares in Ellex at \$1.05 per share to raise a total of approximately \$23.6 million.

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Andrew Angus
M +61 402 823 757
andrewangus@overlandadvisers.com.au

Maria Maieli, CFO & Company Secretary
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8200
mmaieli@ellex.com